{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8652465_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"015-971-490-969-830","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8590,"type":"PATENT","title":"Harvard University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21990,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-04T04:19:00Z","updated":"2022-09-08T02:14:43Z","lastEventDate":"2022-09-08T02:14:43Z"},{"id":11617,"type":"PATENT","title":"Emory University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6117,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8292,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
Search Applicants and Owners separately: emory AND uni*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5631
administering to said subject having an existing persistent viral infection an effective amount of an agent that reduces PD-1 activity, wherein the agent consists of an anti-PD-L1 antibody, wherein said subject is not administered an anti-PD-L2 antibody,\n
thereby reducing viral titer in the subject with the existing persistent viral infection."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said viral infection is an infection with a human immunodeficiency virus (HIV)."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti-PD-L1 antibody reduces the interaction between PD-1 and PD-L1."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said anti -PD-L1 antibody increases the cytotoxic T-cell activity in said subject."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein said cytotoxic T-cell activity is cytokine production or T cell proliferation."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein said cytokine is IFNγ, TNFα, or IL-2."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said antibody is a monoclonal antibody, a humanized antibody, a deimmunized antibody, or an Ig fusion protein."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to said subject a second compound, wherein said second compound is a reverse transcriptase inhibitor, a protease inhibitor, an antibacterial compound, an antifungal compound, an anti-parasitic compound, an anti-inflammatory compound, an anti-neoplastic compound or an analgesic."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to said subject a second compound, wherein said second compound reduces the expression or activity of cytotoxic T lymphocyte antigen 4 (CTLA-4) or B and T lymphocyte attenuator (BTLA)."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to said subject a second compound, wherein said second compound is an anti-CTLA-4 antibody, an anti-BTLA antibody, or an anti-B7-H4 antibody."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said subject is a human."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the reduction of PD-1 activity is assessed by measuring CD8+T cell proliferation, CD8+T cell activity, or both in a sample from said subject."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the reduction of PD-1 activity is assessed by measuring the cytotoxic activity of anergic CD8+T cells in a sample from said subject."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, comprising measuring viral titer in a sample from said subject."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, further comprising administering to the subject an effective amount of a reverse transcriptase inhibitor."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method consists of administering to the subject an effective amount of an anti-PD-L1 antibody."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 16, wherein said viral infection is an infection with a human immunodeficiency virus (HIV)."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method consists of administering to the subject an effective amount of an anti-PD-L1 antibody and a second compound, wherein the second compound is selected from the group consisting of a reverse transcriptase inhibitor, a protease inhibitor, an antibacterial compound, an antifungal compound, an anti-parasitic compound, an anti-inflammatory compound, an anti-neoplastic compound and an analgesic."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein said viral infection is an infection with a human immunodeficiency virus (HIV)."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method consists of administering to the subject an effective amount of an anti-PD-L1 antibody and an anti-viral compound, wherein the anti-viral compound is selected from the group consisting of vidarabine, acyclovir, ganciclovir, valganciclovir, a nucleoside-analog reverse transcriptase inhibitor, a non-nucleoside -reverse transcriptase inhibitor, or a protease inhibitor, and wherein said viral infection is an infection with a human immunodeficiency virus (HIV)."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the reduction of PD-1 activity is assessed by measuring the production of a cytokine by T cells in a sample from said subject."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein the cytokine is interferon γ, tumor necrosis factor α or interleukin-2."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the reduction of PD-1 activity is assessed by measuring induction of the co-stimulation of T cells in a sample from said subject."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the reduction of PD-1 activity is assessed by measuring a B cell response in a sample from said subject."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein PD-1 activity is reduced on CD8+T cells."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 25, wherein the CD8+ cell are memory T cells."],"number":26,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}